Physician profile
John L Fye
NPI 1629053756
$3,065.21
in general payments reported to CMS, 2019-2025
35 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $181 · 2021: $318 · 2022: $531 · 2023: $643 · 2024: $232 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.06 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $521.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $319.29 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $233.60 | 2019-2025 | |
| Novo Nordisk INC | $194.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $193.61 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $184.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.12 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $135.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $96.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.34 | 2019-2023 | |
| Abbott Laboratories | $82.30 | 2021-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $81.81 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.96 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $54.55 | 2020-2025 | Farxiga |
| Edwards Lifesciences Corporation | $53.48 | 2023 | Sapien 3 Ultra Resilia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.98 | 2019-2023 | Rotateq, Gardasil 9, Vaxelis |
| Sanofi-Aventis U.S. LLC | $51.45 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.22 | 2022-2023 | |
| Dexcom, INC. | $47.52 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $42.30 | 2022 | |
| Sumitomo Pharma America, INC. | $39.73 | 2023-2025 | Gemtesa |
| Allergan, INC. | $38.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.87 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $29.55 | 2021 | |
| Neurocrine Biosciences, INC. | $25.79 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.71 | 2019 | |
| Exact Sciences Corporation | $21.58 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $20.62 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $19.52 | 2025 | Jornay Pm |
| Esperion Therapeutics, INC. | $15.91 | 2025 | Nexletol |
| Shield Therapeutics INC | $14.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.07 | 2025 | Rexulti |
| Astellas Pharma US INC | $13.38 | 2023 | Veozah |
| Medtronic, INC. | $13.11 | 2022 | |
| Antares Pharma, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.